Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.

JAMA Netw Open. 2019 Apr 5;2(4):e192416. doi:10.1001/jamanetworkopen.2019.2416.

Pedersen AB, Heide-Jørgensen U, Sørensen HT, Prieto-Alhambra D, Ehrenstein V.

https://www.ncbi.nlm.nih.gov/pubmed/31002319
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen